Sona Nanotech (CSE:SONA)- CEO, David Regan
CEO, David Regan
Source: Entrevestor
  • Sona Nanotech (SONA) is planning to raise up to C$2 million to support the development of its rapid COVID-19 antigen test
  • The company intends to issue 2 million units at a price of $1.00 each, consisting of one common share and one-half of a share purchase warrant
  • Each whole warrant will be exercisable at a price of $1.25 per share for a period of 24 months
  • In addition to the financing, the company has appointed Obelis SA to complete the CE Marking process for its In-Vitro Diagnostic Devices in the European Union
  • Sona Nanotech is currently down 2.94 per cent to $0.99 per share

Sona Nanotech (SONA) is planning to raise up to C$2 million to support the development of its rapid COVID-19 antigen test.

Under the terms of the financing, the Halifax-based diagnostic test developer intends to issue 2 million units at a price of $1.00 each. These units will be comprised of one common share in Sona Nanotech as well as one-half of a common share purchase warrant.

Each whole warrant will be exercisable at a price of $1.25 per share for a period of 24 months from the date of issuance.

According to today’s release, the proceeds will be used primarily to produce further clinical trial data for its rapid COVID-19 antigen nasal pharyngeal test and to pursue additional clinical trial validation work for a saliva-based version of the test.

A portion of the funds will also be used to pursue a European regulatory self-certification CE Mark declaration, for which Obelis SA has been appointed to complete.

Since 1988, Obelis – a regulatory and compliance consulting service provider – has helped more than 3,000 manufacturers from over 60 countries to introduce their products to the European market.

Sona Nanotech will now work with Obelis – as an authorised representative – to compile the necessary technical documentation to show that the company’s In-Vitro Diagnostic Devices meet the necessary CE Marking requirements.

Sona Nanotech also said it will work with its contracted manufacturer to complete its technology transfer batch production runs.

Using a pregnancy-type lateral flow test that eliminates the need for laboratory equipment or specially-trained health professionals, the company’s rapid COVID-19 antigen test is capable of producing results in as little as 15 minutes.

Sona Nanotech is currently down 2.94 per cent to $0.99 per share at 12:13pm EST.

More From The Market Online
Image description: an AI generated photo with a stethoscope

WELL Health receives C$15.3 million in funding for AI healthtech

WELL Health Technologies (TSX:WELL) locks in C$15.3 million in funding for a project to develop artificial intelligence health technology.
Theratechnologies image of a lab technician handling samples

Theratechnologies stock jumps on positive income report

Theratechnologies stock (TSX:TH) opens nearly 4 per cent higher on Wednesday on the release of its latest financial results.